title: Long-term follow-up of 23 patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with allogeneic bone marrow transplant in first complete remission.
abstract: Between 1984 and 1997, 23 consecutive patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in first complete remission were treated with allogeneic bone marrow transplants from HLA-matched siblings. All patients but one were conditioned with fractionated total body irradiation (1320 cGy) and high-dose etoposide (60 mg/kg). One patient received high-dose cyclophosphamide instead of etoposide, and another patient received both drugs. Nine patients died following BMT, two from relapsed leukemia, and seven from transplant-related causes. The 3-year probabilities of disease-free survival and relapse are 65% and 12%, respectively. For patients transplanted after 1992, these probabilities are 81% (48-95%, 95% confidence interval) and 11% (2-50%), respectively. The relatively low relapse rate in this group of patients compared to published reports may reflect the enhanced anti-leukemic activity of etoposide in combination with FTBI compared to other conditioning regimens. The enhancement in overall survival for patients transplanted after 1992 may reflect improvements in supportive care, in particular, the prophylaxis of serious fungal and viral infections.
authors.affiliation: Department of Hematology/Bone Marrow Transplantation, City of Hope National Medical Center, Duarte, CA 91010, USA.
authors.forename: D S
authors.initials: DS
authors.lastname: Snyder
authors.forename: A P
authors.initials: AP
authors.lastname: Nademanee
authors.forename: M R
authors.initials: MR
authors.lastname: O'Donnell
authors.forename: P M
authors.initials: PM
authors.lastname: Parker
authors.forename: A S
authors.initials: AS
authors.lastname: Stein
authors.forename: K
authors.initials: K
authors.lastname: Margolin
authors.forename: G
authors.initials: G
authors.lastname: Somlo
authors.forename: A
authors.initials: A
authors.lastname: Molina
authors.forename: R
authors.initials: R
authors.lastname: Spielberger
authors.forename: A
authors.initials: A
authors.lastname: Kashyap
authors.forename: H
authors.initials: H
authors.lastname: Fung
authors.forename: M L
authors.initials: ML
authors.lastname: Slovak
authors.forename: A
authors.initials: A
authors.lastname: Dagis
authors.forename: R S
authors.initials: RS
authors.lastname: Negrin
authors.forename: M D
authors.initials: MD
authors.lastname: Amylon
authors.forename: K G
authors.initials: KG
authors.lastname: Blume
authors.forename: S J
authors.initials: SJ
authors.lastname: Forman
mesh_terms: D000328:Adult; D016026:Bone Marrow Transplantation; D002648:Child; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D016044:Fusion Proteins, bcr-abl / Q000235:genetics; D006801:Humans; D008297:Male; D016133:Polymerase Chain Reaction; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000401:mortality / Q000628:therapy*; D012008:Recurrence; D014184:Transplantation, Homologous
chemical_list: D016044:Fusion Proteins, bcr-abl